The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Linezolid for Oral Suspension (5ml:100mg) from National Medical Products Administration of China, being under type 4 chemical drug and regarded as passing the consistency evaluation. Linezolid for Oral Susp Extension is a suspension in oral dosage form. The Group was the first in obtaining such approval for the PRC entities, and has previously obtained the production approvals for Linezolid bulk drug and injections.

Linezolid for Oral suspension can be used in newborn, child and adult patients, and is mainly used in the treatment of hospital-acquired pneumonia, community-acquired pneumonia, skin and soft tissue infections and vancomycin-resistant Enterococcus facadeecium infections which are caused by susceptible strains of specific microorganisms. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.